Selecta Biosciences, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Selecta Biosciences, Inc.
The last quarter of 2023 was an exciting one for the cell and gene therapy sector – with the first-ever approval for a CRISPR-based therapeutic in the US and an increase in Phase III trials in the overall CGT pipeline.
Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.
Commission pursued merger challenge to halt pharma practices it believes can stifle competition and keep drug prices high. Other large biopharma transactions may face similar challenges as FTC pursues its new merger program.
- Gene Therapy, Cell Therapy
- Large Molecule
- Nanotechnology, Chips, etc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.